Search peptides, terms, sources/
Immune and longevity

MOTS-c

Also known as: Mitochondrial open reading frame of the 12S rRNA-c

16-amino-acid peptide encoded in mitochondrial DNA, studied in mice and cells. Not licensed in the UK. No published trial gave MOTS-c to people; human studies measured the body's own levels.

UK status and evidence last reviewed .

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Preliminary evidence (level 1 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

4 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. MOTS-c is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials1 human trial · 1 human observational · 2 animal studies

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, studied in mice and cells for effects on insulin sensitivity, obesity and exercise capacity. It is not licensed in the UK, and no published trial in which people were given MOTS-c was found; the human studies measure the body's own MOTS-c levels.

Class
Mitochondrial-derived peptide
Origin
Endogenous
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does MOTS-c work?

In the 2015 discovery paper, MOTS-c acted mainly on skeletal muscle in mice and, in cells, blocked the folate cycle, which switched on an energy-sensing enzyme called AMPK. A 2021 study in mice and muscle cells reported changes in the activity of nuclear genes involved in metabolism. All of this is animal and cell work, a proposed mechanism not shown to apply to people who receive MOTS-c.

The mechanism in more detail

MOTS-c is encoded by mitochondrial DNA. In the 2015 discovery paper, the authors report that the primary target organ appears to be skeletal muscle and that, in cells, MOTS-c inhibits the folate cycle and the linked purine-building pathway, which activates the energy-sensing enzyme AMPK (Lee et al., Cell Metabolism). In mice, treatment prevented diet-induced obesity and insulin resistance in that paper.

A 2021 study in mice and muscle cells reported that MOTS-c changed the activity of nuclear genes involved in metabolism and protein quality control (Reynolds et al., Nature Communications). All of this is animal and cell work; it is a proposed mechanism and has not been shown to apply to people who receive MOTS-c.

Mechanisms and targets

AMPK activation / folate-cycle inhibition (proposed, cell work)Skeletal muscle (primary target organ proposed in mice)

Classification and structure

Names
MOTS-c; Mitochondrial open reading frame of the 12S rRNA-c
Class
Mitochondrial-derived peptide
Origin
Endogenous
Structure
A 16-amino-acid peptide encoded by a short open reading frame in the mitochondrial 12S rRNA gene (Lee et al., Cell Metabolism 2015).
Routes used in the research
Not applicable to the human studies cited, which measured the body's own MOTS-c. The route used in the animal studies was not read.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

MOTS-c has 4 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

4 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
40000

Discovery paper, mice and cells Preliminary

The 2015 discovery paper identified MOTS-c as a 16-amino-acid peptide encoded in mitochondrial DNA. In mice, MOTS-c treatment prevented age-related and high-fat-diet-induced insulin resistance and diet-induced obesity. In cells it activated AMPK. The abstract reports no human experiments.

Study type
Animal
Population
Mice and cultured cells; no human experiments in the abstract.
Source
1 Lee et al., 2015

Limitation: Animal and cell work only.

Limitations in full

Animal and cell work only. Mouse results often fail to carry over to people. Abstract read via Europe PMC; full text not read, so sample sizes are unknown.

Exercise and ageing in mice Preliminary

A 2021 study reported that MOTS-c improved physical performance in mice aged 2, 12 and 22 months, and that treatment started late in life increased physical capacity in old mice. The same paper found that exercise raised the body's own MOTS-c in human skeletal muscle and blood.

Study type
Animal
Population
Mice at three ages and cultured muscle precursor cells; human samples showed only that exercise raised natural MOTS-c.
Source
2 Reynolds et al., 2021

Limitation: The treatment effect was shown in mice only.

Limitations in full

The treatment effect was shown in mice only. The human data show that exercise raises natural MOTS-c, not that giving MOTS-c improves anything. Abstract read via Europe PMC; full text not read.

Human exercise trial measured MOTS-c Preliminary

In a secondary analysis of a randomised 16-week exercise trial in 49 breast cancer survivors, plasma MOTS-c rose after exercise in Non-Hispanic White participants, and higher MOTS-c was linked to reductions in fat mass and insulin resistance. In Hispanic participants the rise was not significant. The study did not give anyone MOTS-c and cannot say why the groups differed.

Study type
Human trial
Population
49 breast cancer survivors (25 Hispanic, 24 Non-Hispanic White); secondary analysis of a randomised exercise trial.
Source
3 Dieli-Conwright et al., 2021

Limitation: The intervention was exercise, not MOTS-c.

Limitations in full

The intervention was exercise, not MOTS-c. Small groups; associations do not show that MOTS-c caused the changes. Abstract read via Europe PMC; full text not read.

Higher natural MOTS-c in obesity Preliminary

In a small 2026 exploratory study, circulating MOTS-c was higher in 32 adults with obesity than in 22 lean adults (273 versus 223 pg/mL) and tracked with BMI and insulin resistance. It did not change in the 10 people re-measured 6 months after weight-loss surgery. The authors call it preliminary and suggest MOTS-c may be a compensatory response or a biomarker.

Study type
Human observational
Population
22 lean adults and 32 adults with obesity awaiting bariatric surgery; 10 re-measured after surgery; adipose-tissue measures in a smaller subgroup.
Source
4 Yoon et al., 2026

Limitation: Association only, small groups, and the authors ask for larger independent cohorts.

Limitations in full

Association only, small groups, and the authors ask for larger independent cohorts. It does not test giving MOTS-c. Abstract read via Europe PMC; full text not read.

What safety findings have been reported?

No safety findings are recorded for MOTS-c yet. That is not evidence of safety.

What is MOTS-c's UK regulatory status?

Marketing authorisation
None identified. MOTS-c does not appear in the MHRA Products database active-substance index (checked 14 November 2026).
Prescription status
Not applicable; there is no licensed UK product to classify.
Medicine class
Not a licensed medicine in the UK.
MHRA position
No MHRA-authorised product containing MOTS-c was found in the Products database on 14 November 2026. Absence from the index is a search result on that date, not a regulatory decision.
Authorised use
None.
Research use
Studied in laboratory and animal research. The sources reviewed report no human trial in which MOTS-c itself was given; the human studies measure the body's own levels.
Other restrictions
None identified beyond the general Human Medicines Regulations 2012 framework. In sport, the WADA 2026 Prohibited List (in force from 1 January 2026) names MOTS-c under S4.4.1, metabolic modulators.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. MOTS-c is recorded as not licensed in the UK (checked 14 November 2026).

References

5 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Lee C, Zeng J, Drew BG, et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell MetabolismAnimal-preclinical, In-vitro · DOI 10.1016/j.cmet.2015.02.009 · PMID 25738459 · Original ↗
  2. Reynolds JC, Lai RW, Woodhead JST, et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature CommunicationsAnimal-preclinical, In-vitro · DOI 10.1038/s41467-020-20790-0 · PMID 33473109 · Original ↗
  3. Dieli-Conwright CM, Sami N, Norris MK, et al. (2021). Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Scientific ReportsHuman observational, RCT · DOI 10.1038/s41598-021-96419-z · PMID 34413391 · Original ↗
  4. Yoon SH, Yuan F, Zhu X, et al. (2026). Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss. Journal of Clinical & Translational EndocrinologyHuman observational · DOI 10.1016/j.jcte.2025.100429 · PMID 41551324 · Original ↗
  5. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about MOTS-c

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, studied in mice and cells for effects on insulin sensitivity, obesity and exercise capacity. It is not licensed in the UK, and no published trial in which people were given MOTS-c was found; the human studies measure the body's own MOTS-c levels. Read what it is.

Is MOTS-c licensed in the UK?

PeptGuru records MOTS-c's UK status as: Not licensed in the UK. None identified. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on MOTS-c show?

PeptGuru records 4 research findings for MOTS-c: 1 from a human trial, 1 from a human observational study and 2 from animal studies. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for MOTS-c?

No safety findings are recorded yet. That is not evidence of safety. Read the safety findings.

Where are the sources for MOTS-c?

All 5 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • New profile · MOTS-c added: 4 findings and 0 safety items, each checked against its published record, with UK status checked on the MHRA register.

How findings are graded: the grading method. All changes.

  • EpithalonEpitalon

    Synthetic four-amino-acid peptide studied in ageing research. Not licensed in the UK; evidence is mostly laboratory and animal work from one group.

    Immune and longevityHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • AOD-9604hGH Fragment 176-191

    Growth hormone fragment studied for weight management. Not licensed in the UK; its largest human trial showed no significant weight-loss benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • CagrilintideAM833

    Not licensed in the UK. Investigational long-acting amylin analogue studied for weight management, alone and with semaglutide.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • GHK-CuCopper peptide GHK

    Copper-binding tripeptide studied for skin ageing and wound healing. Topical cosmetic use; no licensed injectable product in the UK.

    Repair and regenerationHuman trialsEvidence reviewed
    LimitedNot licensed in the UK

Compare MOTS-c with Epithalon

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.